Please login to the form below

Not currently logged in
Email:
Password:

GSK increases stake in Theravance

GlaxoSmithKline has spent $2m on shares in biopharmaceutical company Theravence, increasing its stake to 19.01 per cent

GlaxoSmithKline (GSK) has spent $2m on shares in biopharmaceutical company Theravence, increasing its stake to 19.01 per cent.

GSK purchased 102,466 shares of common stock of the US-based company at a price of $19.71 per share.

The investment is part of GSK's right to acquire, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in Theravance.

Theravance specialises in multivalency - the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets.

In March 2004, GSK and Theravence entered into a strategic alliance where GSK received an option to license product candidates from Theravance's drug discovery programmes initiated prior to September 1, 2007, on an exclusive, worldwide basis.

GSK is responsible for funding all future development, manufacturing and commercialisation activities for product candidates in that programme once it is licensed.

As well as its projects with GSK, Theravence is currently working with Astellas for the global development and commercialization of antibacterial Vibativ (telavancin).

4th August 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...